5 October 2018 - Express Scripts’ Accredo selected as specialty pharmacy for its expertise in providing timely access and support services for patients living with rare diseases.
Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, announced today that they are working together with Accredo specialty pharmacy, a subsidiary of Express Scripts, to distribute Tegsedi (inotersen) subcutaneous injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Approved by the U.S. FDA today, Tegsedi is the first and only subcutaneous RNA-targeting therapeutic offering patients an effective treatment for the polyneuropathy of hATTR amyloidosis. Subcutaneous delivery represents a significant new option for the patients, caregivers, and healthcare professionals in the U.S. and making Tegsedi widely available to patients is now a critical next step. Akcea chose Express Scripts’ Accredo because of its experience supporting the unique needs of rare disease communities and its proven track record for simplifying access to therapy.